Here you go... again.
I posted it earlier today already, but I guess facts get in the way of your narrative all to easy.
FDA never required another trial.
"the FDA recommended that Mesoblast conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD"
2023 The Final Countdown, page-1241
-
- There are more pages in this discussion • 2,163 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.005(0.47%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.10 | $1.06 | $3.371M | 3.135M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 45345 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 3875 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |